Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 4
2009 12
2010 16
2011 14
2012 15
2013 17
2014 30
2015 47
2016 38
2017 32
2018 46
2019 41
2020 28
2021 23
2022 12
Text availability
Article attribute
Article type
Publication date

Search Results

350 results
Results by year
Filters applied: . Clear all
Page 1
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
Avihingsanon A, Hughes MD, Salata R, Godfrey C, McCarthy C, Mugyenyi P, Hogg E, Gross R, Cardoso SW, Bukuru A, Makanga M, Badal-Aesen S, Mave V, Ndege BW, Fontain SN, Samaneka W, Secours R, Van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Munyanga C, Chagomerana M, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, Grinsztejn B; A5288 Study team. Avihingsanon A, et al. J Int AIDS Soc. 2022 Jun;25(6):e25905. doi: 10.1002/jia2.25905. J Int AIDS Soc. 2022. PMID: 36039892 Free PMC article.
Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden Settings.
Gupta A, Sun X, Krishnan S, Matoga M, Pierre S, McIntire K, Koech L, Faesen S, Kityo C, Dadabhai SS, Naidoo K, Samaneka WP, Lama JR, Veloso VG, Mave V, Lalloo U, Langat D, Hogg E, Bisson GP, Kumwenda J, Hosseinipour MC; ACTG A5274/REMEMBER Study Team. Gupta A, et al. Open Forum Infect Dis. 2022 Jul 3;9(7):ofac325. doi: 10.1093/ofid/ofac325. eCollection 2022 Jul. Open Forum Infect Dis. 2022. PMID: 35899273 Free PMC article.
Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial.
Baltrusaitis K, Makanani B, Tierney C, Fowler MG, Moodley D, Theron G, Nyakudya LH, Tomu M, Fairlie L, George K, Heckman B, Knowles K, Browning R, Siberry GK, Taha TE, Stranix-Chibanda L; PROMISE P1084s Study Team. Baltrusaitis K, et al. BMC Infect Dis. 2022 Jul 20;22(1):634. doi: 10.1186/s12879-022-07608-8. BMC Infect Dis. 2022. PMID: 35858874 Free PMC article. Clinical Trial.
Effects of long-term antiretroviral therapy in reproductive-age women in sub-Saharan Africa (the PEPFAR PROMOTE study): a multi-country observational cohort study.
Taha TE, Yende-Zuma N, Brummel SS, Stranix-Chibanda L, Wambuzi Ogwang L, Dadabhai S, Chinula L, Nyati MM, Hanley S, Makanani B, Chipato T, Atuhaire P, Aizire J, Fowler MG. Taha TE, et al. Lancet HIV. 2022 Jun;9(6):e394-e403. doi: 10.1016/S2352-3018(22)00037-6. Epub 2022 Apr 27. Lancet HIV. 2022. PMID: 35489365
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E, Mpendo J, Mukwekwerere P, Mgodi N, Ntege PN, Nair G, Nakabiito C, Nuwagaba-Biribonwoha H, Panchia R, Singh N, Siziba B, Farrior J, Rose S, Anderson PL, Eshleman SH, Marzinke MA, Hendrix CW, Beigel-Orme S, Hosek S, Tolley E, Sista N, Adeyeye A, Rooney JF, Rinehart A, Spreen WR, Smith K, Hanscom B, Cohen MS, Hosseinipour MC; HPTN 084 study group. Delany-Moretlwe S, et al. Lancet. 2022 May 7;399(10337):1779-1789. doi: 10.1016/S0140-6736(22)00538-4. Epub 2022 Apr 1. Lancet. 2022. PMID: 35378077 Free PMC article. Clinical Trial.
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
Eshleman SH, Fogel JM, Piwowar-Manning E, Chau G, Cummings V, Agyei Y, Richardson P, Sullivan P, Haines CD, Bushman LR, Petropoulos C, Persaud D, Kofron R, Hendrix CW, Anderson PL, Farrior J, Mellors J, Adeyeye A, Rinehart A, St Clair M, Ford S, Rooney JF, Mathew CA, Hunidzarira P, Spooner E, Mpendo J, Nair G, Cohen MS, Hughes JP, Hosseinipour M, Hanscom B, Delany-Moretlwe S, Marzinke MA. Eshleman SH, et al. J Infect Dis. 2022 May 16;225(10):1741-1749. doi: 10.1093/infdis/jiab576. J Infect Dis. 2022. PMID: 35301540 Clinical Trial.
Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy.
Hawkins C, Kang M, Bhattacharya D, Cloherty G, Kuhns M, Matining R, Thio C, Samaneka W, Chinula L, Mulinda N, Badal-Faesen S, Sugandhavesa P, Lama J, Gaseitsiwe S, Holzmayer V, Anderson M, Murphy R, Peters M. Hawkins C, et al. AIDS. 2022 Jun 1;36(7):975-984. doi: 10.1097/QAD.0000000000003193. Epub 2022 Feb 14. AIDS. 2022. PMID: 35165216
Ring-ing in the Future: Participant and Male Partner Perspectives Regarding Future Use of the Dapivirine Vaginal Ring for HIV Prevention.
Reddy K, Mathebula F, Katz A, Luecke E, Tenza S, Palanee-Phillips T, Garcia M, Mansoor LE, Naidoo S, Morar N, Chitukuta M, Tsidya M, Montgomery ET; MTN-032 Study team. Reddy K, et al. AIDS Behav. 2022 Jun;26(6):1923-1932. doi: 10.1007/s10461-021-03542-z. Epub 2022 Jan 22. AIDS Behav. 2022. PMID: 35064389 Free PMC article.
350 results